DK2034839T3 - Behandling af neurodegenerative sygdomme ved hæmning af hsp90 - Google Patents

Behandling af neurodegenerative sygdomme ved hæmning af hsp90 Download PDF

Info

Publication number
DK2034839T3
DK2034839T3 DK07812557.2T DK07812557T DK2034839T3 DK 2034839 T3 DK2034839 T3 DK 2034839T3 DK 07812557 T DK07812557 T DK 07812557T DK 2034839 T3 DK2034839 T3 DK 2034839T3
Authority
DK
Denmark
Prior art keywords
tau
hsp90
compound
disease
brain
Prior art date
Application number
DK07812557.2T
Other languages
English (en)
Inventor
Gabriela Chiosis
Paul Greengard
Fei Dou
Wenjie Luo
Original Assignee
Sloan-Kettering Institute For Cancer Res
Univ Rockefeller
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sloan-Kettering Institute For Cancer Res, Univ Rockefeller filed Critical Sloan-Kettering Institute For Cancer Res
Application granted granted Critical
Publication of DK2034839T3 publication Critical patent/DK2034839T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/40—Heterocyclic compounds containing purine ring systems with halogen atoms or perhalogeno-alkyl radicals directly attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Claims (15)

1. Forbindelse valgt fra gruppen, der består af: PU-BSI12, PU-BSI8, PU-BSI6, PU-BSI11, PU-BSI7, PU-BSI13, PU-BSI14, PU-BSI5, PU-HZ150, PU-HZ151, PU-DZ13, PU-DZ14 og PU- DZ16 med følgende formler:
PU-BSI12 PU-BS13 PU-BSI6
PU-BSI11 PU-BSS7
PU-BSI13 PU-BSI14 PU-BSI5 ^ PU-HZ150
PU-HZ151 PU-DZ13 PU-DZ14
PU-DZ16 til anvendelse til behandling af neurodegenerativ sygdom.
2. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen er PU-HZ150.
3. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen er PU-HZ151.
4. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen er PU-BSI5.
5. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen er PU-DZ13.
6. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen er PU-DZ14.
7. Forbindelse til anvendelse ifølge krav 1, hvor forbindelsen er PU-BSI-11.
8. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 7, hvor forbindelsen krydser blod-hjerne-barrieren.
9. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor den neurodegenerative sygdom er valgt fra gruppen, der består af alkoholinduceret neurodegeneration; Alzheimers sygdom; amyotrofisk lateral sklerose; hjerneiskæmi; kokainafhængighed; diffus Lewybody-sygdom; elektrokonvulsive anfald; føtalt alkoholsyndrom; fokal kortikal dysplasi; arvelig spinal muskelatrofi hos hunde; inklusionslegeme-myositis; Shy-Drager-syndrom; Niemann-Pick type C; Parkinsons sygdom; og perifer nerveskade.
10. Forbindelse til anvendelse ifølge krav 9, hvor den neurodegenerative sygdom er Alzheimers sygdom.
11. Forbindelse til anvendelse ifølge et hvilket som helst af kravene 1 til 8, hvor den neurodegenerative sygdom er en tauopati.
12. Anvendelse af en forbindelse ifølge et hvilket som helst af kravene 1 til 8 til fremstilling af et medikament til behandling af neurodegenerativ sygdom.
13. Anvendelse ifølge krav 12, hvor den neurodegenerative sygdom er valgt fra gruppen, der består af alkoholinduceret neurodegeneration; Alzheimers sygdom; amyotrofisk lateral sklerose; hjerneiskæmi; kokainafhængighed; diffus Lewybody-sygdom; elektrokonvulsive anfald; føtalt alkoholsyndrom; fokal kortikal dysplasi; arvelig spinal muskelatrofi hos hunde; inklusionslegeme-myositis; Shy-Drager-syndrom; Niemann-Pick type C; Parkinsons sygdom; og perifer nerveskade.
14. Anvendelse ifølge krav 13, hvor den neurodegenerative sygdom er Alzheimers sygdom.
15. Anvendelse ifølge krav 12, hvor den neurodegenerative sygdom er en tauopati.
DK07812557.2T 2006-06-30 2007-07-02 Behandling af neurodegenerative sygdomme ved hæmning af hsp90 DK2034839T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US80642706P 2006-06-30 2006-06-30
PCT/US2007/072671 WO2008005937A2 (en) 2006-06-30 2007-07-02 Treatment of neurodegenerative diseases through inhibiton of hsp90

Publications (1)

Publication Number Publication Date
DK2034839T3 true DK2034839T3 (da) 2017-12-04

Family

ID=38895418

Family Applications (1)

Application Number Title Priority Date Filing Date
DK07812557.2T DK2034839T3 (da) 2006-06-30 2007-07-02 Behandling af neurodegenerative sygdomme ved hæmning af hsp90

Country Status (8)

Country Link
US (4) US10336757B2 (da)
EP (2) EP3305297A1 (da)
JP (5) JP5599610B2 (da)
AU (1) AU2007269144B2 (da)
CA (1) CA2656202C (da)
DK (1) DK2034839T3 (da)
ES (1) ES2645095T3 (da)
WO (1) WO2008005937A2 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) * 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
AU2007249194B2 (en) * 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
EP3305297A1 (en) 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
MX2009009936A (es) 2007-03-20 2010-02-11 Curis Inc Amino piridina fusionada como inhibidores de hsp90.
CN101909440A (zh) * 2007-11-14 2010-12-08 瑞科西有限公司 治疗用化合物及其在治疗疾病和障碍中的用途
US20090258869A1 (en) * 2008-02-08 2009-10-15 The Regents Of The University Of California Methods and compounds for treatment or prevention of substance-related disorders
PL2659904T3 (pl) 2008-06-26 2016-01-29 Orphazyme Aps Zastosowanie Hsp70 jako regulatora aktywności enzymatycznej
EP2440204B1 (en) 2009-06-12 2013-12-18 Bristol-Myers Squibb Company Nicotinamide compounds useful as kinase modulators
AU2013204109B2 (en) * 2009-10-07 2016-05-05 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
PL2646044T3 (pl) 2010-11-30 2020-03-31 Orphazyme A/S Sposoby zwiększenia aktywności wewnątrzkomórkowej Hsp70
JP5961683B2 (ja) * 2011-04-05 2016-08-02 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
CA2841173C (en) * 2011-07-08 2022-06-21 Sloan-Kettering Institute For Cancer Research Uses of labeled hsp90 inhibitors
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP2879675B1 (en) 2012-08-06 2019-11-13 Duke University Compounds and methods for targeting hsp90
MX361136B (es) 2013-01-23 2018-11-28 Astrazeneca Ab Compuestos quimicos.
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
SG11201601542SA (en) * 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof
AU2014318826B2 (en) 2013-09-10 2019-10-10 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
TWI673279B (zh) 2013-12-23 2019-10-01 美國紀念斯隆-凱特琳癌症中心 用於放射性標記之方法及試劑
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
JP6678676B2 (ja) 2014-09-15 2020-04-08 オーファザイム エー／エス アリモクロモル製剤
MX2017003513A (es) * 2014-09-17 2017-07-28 Memorial Sloan Kettering Cancer Center Formación de imágenes de inflamación e infección dirigida a hsp90 y terapia.
WO2017062520A1 (en) 2015-10-05 2017-04-13 Memorial Sloan Kettering Cancer Center Rational combination therapy for the treatment of cancer
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
WO2017184956A1 (en) 2016-04-22 2017-10-26 Duke University Compounds and methods for targeting hsp90
EP3448382B1 (en) 2016-04-29 2020-10-14 Orphazyme A/S Arimoclomol for treating glucocerebrosidase associated disorders
EA201992215A1 (ru) 2017-03-20 2020-02-06 Форма Терапьютикс, Инк. Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr)
CN110996918A (zh) * 2017-04-24 2020-04-10 萨缪斯治疗股份有限公司 Hsp90抑制剂口服配制品和相关方法
EP3641782A4 (en) 2017-06-20 2021-03-24 Madrigal Pharmaceuticals, Inc. COMBINED THERAPIES INCLUDING TARGETED THERAPEUTICS
JP2020524154A (ja) 2017-06-20 2020-08-13 マドリガル ファーマシューティカルズ インコーポレイテッドＭａｄｒｉｇａｌ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 標的治療薬
CN111683658A (zh) * 2017-06-23 2020-09-18 萨缪斯治疗股份有限公司 用于创伤性脑损伤及其后遗症的多蛋白复合物抑制剂疗法
ES2910071T3 (es) 2018-03-08 2022-05-11 Incyte Corp Compuestos de aminopirazina diol como inhibidores de PI3K-Y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
EP3852791A4 (en) 2018-09-19 2022-06-15 Forma Therapeutics, Inc. ACTIVATION OF PYRUVATE KINASE R
US20220031671A1 (en) 2018-09-19 2022-02-03 Forma Therapeutics, Inc. Treating sickle cell disease with a pyruvate kinase r activating compound
US20230416224A1 (en) 2020-11-19 2023-12-28 Zevra Denmark A/S Processes for preparing arimoclomol citrate and intermediates thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998051702A1 (en) 1997-05-14 1998-11-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins
CA2370007A1 (en) 1999-04-09 2000-10-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases
CN1501928A (zh) * 2000-11-02 2004-06-02 斯隆-凯特林癌症研究所 结合hsp90的小分子组合物
WO2002094259A1 (en) * 2001-05-03 2002-11-28 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Compounds that inhibit hsp90 and stimulate hsp70 and hsp40, useful in the prevention or treatment of diseases associated with protein aggregation and amyloid formation
EP1440072A4 (en) 2001-10-30 2005-02-02 Conforma Therapeutic Corp PURINE ANALOGS HAVING HSP90 INHIBITORY ACTIVITY
AU2002356922A1 (en) 2001-11-09 2003-05-26 Conforma Therapeutics Corporation Hsp90-inhibiting zearalanol compounds and methods of producing and using same
KR20040087329A (ko) * 2002-02-28 2004-10-13 아스트라제네카 아베 3-시클릴-5-(질소-함유 5-원 고리) 메틸-옥사졸리디논유도체 및 그의 항균제로서의 용도
CA2522700A1 (en) 2003-04-18 2004-11-04 Cytovia, Inc. Methods of treating diseases responsive to induction of apoptosis and screening assays
GB0315111D0 (en) 2003-06-27 2003-07-30 Cancer Rec Tech Ltd Substituted 5-membered ring compounds and their use
WO2005012482A2 (en) 2003-06-30 2005-02-10 Sloan-Kettering Institute For Cancer Research Assay for identification of bioactive compounds that interact with heat shock protein 90
BRPI0414533A (pt) * 2003-09-18 2006-11-07 Conforma Therapeutics Corp composto, composição farmacêutica, e, métodos para inibir um hsp90 e para tratar um indivìduo tendo um distúrbio mediado por hsp90
US9403828B2 (en) 2005-02-01 2016-08-02 Sloan-Kettering Institute For Cancer Research Small-molecule Hsp90 inhibitors
WO2006084030A2 (en) 2005-02-01 2006-08-10 Sloan-Kettering Institute For Cancer Research Small-molecule hsp90 inhibitors
CN101180275B (zh) 2005-02-25 2014-09-10 瑟瑞耐克斯有限公司 四氢吲哚酮和四氢吲唑酮衍生物
WO2006130469A1 (en) 2005-05-27 2006-12-07 Oregon Health & Science University Stimulation of neurite outgrowth by small molecules
WO2007117466A2 (en) 2006-03-31 2007-10-18 Massachusetts Institute Of Technology Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
AU2007249194B2 (en) 2006-05-12 2012-11-22 Myrexis, Inc. Therapeutic compounds and their use in cancer
EP3305297A1 (en) 2006-06-30 2018-04-11 Sloan-Kettering Institute for Cancer Research Treatment of neurodegenerative diseases through inhibition of hsp90
WO2008013985A2 (en) 2006-07-27 2008-01-31 University Of Florida Use of heat shock activators for tissue regeneration
KR20090077914A (ko) * 2006-09-11 2009-07-16 쿠리스 인코퍼레이션 항증식제로서의 다작용성 소분자
CL2007002994A1 (es) * 2006-10-19 2008-02-08 Wyeth Corp Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros.
GB0622084D0 (en) 2006-11-06 2006-12-13 Chroma Therapeutics Ltd Inhibitors of HSP90
WO2008070472A2 (en) 2006-11-27 2008-06-12 University Of Maryland, Baltimore Use of plasma hsp90 related to malignancy
WO2008115262A2 (en) * 2007-03-20 2008-09-25 Curis, Inc. Hsp90 inhibitors containing a zinc binding moiety
MX2009009936A (es) * 2007-03-20 2010-02-11 Curis Inc Amino piridina fusionada como inhibidores de hsp90.
EP2183221A1 (en) 2007-07-12 2010-05-12 Crystax Pharmaceuticals S.L. New compounds as hsp90 inhibitors
WO2009042646A1 (en) 2007-09-24 2009-04-02 Curis, Inc. Anti-proliferative agents
CN101909440A (zh) 2007-11-14 2010-12-08 瑞科西有限公司 治疗用化合物及其在治疗疾病和障碍中的用途
WO2011044394A1 (en) 2009-10-07 2011-04-14 Sloan-Kettering Institute For Cancer Research Purine derivatives useful as hsp90 inhibitors
JP5961683B2 (ja) 2011-04-05 2016-08-02 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
US9346808B2 (en) 2011-04-05 2016-05-24 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
SG11201601542SA (en) 2013-08-16 2016-04-28 Sloan Kettering Inst Cancer Selective grp94 inhibitors and uses thereof

Also Published As

Publication number Publication date
CA2656202A1 (en) 2008-01-10
JP2016028063A (ja) 2016-02-25
JP2019038829A (ja) 2019-03-14
JP5824698B2 (ja) 2015-11-25
US20190389864A1 (en) 2019-12-26
JP2009542716A (ja) 2009-12-03
EP2034839B1 (en) 2017-08-23
US20230060990A1 (en) 2023-03-02
AU2007269144A1 (en) 2008-01-10
JP2013177389A (ja) 2013-09-09
EP2034839A2 (en) 2009-03-18
AU2007269144B2 (en) 2013-05-16
WO2008005937A2 (en) 2008-01-10
ES2645095T3 (es) 2017-12-04
JP6427227B2 (ja) 2018-11-21
US20090298857A1 (en) 2009-12-03
JP6585266B2 (ja) 2019-10-02
WO2008005937A3 (en) 2008-12-11
EP3305297A1 (en) 2018-04-11
US20140378452A1 (en) 2014-12-25
JP2017214379A (ja) 2017-12-07
EP2034839A4 (en) 2012-08-29
JP5599610B2 (ja) 2014-10-01
CA2656202C (en) 2018-01-16
US10336757B2 (en) 2019-07-02

Similar Documents

Publication Publication Date Title
US20230060990A1 (en) Treatment of neurodegenerative diseases through inhibiton of hsp90
Nguyen et al. Cycling at the interface between neurodevelopment and neurodegeneration
Brunden et al. Microtubule-stabilizing agents as potential therapeutics for neurodegenerative disease
Šála et al. Novel human neutral sphingomyelinase 2 inhibitors as potential therapeutics for Alzheimer’s disease
US20080312238A1 (en) 4-Arylazo-3,5-Diamino-Pyrazole Compounds and Use Thereof
JP2009535321A (ja) Ｇｓｋ−３阻害剤としてのｎ−（２−チアゾリル）アミド誘導体
JP2011504474A (ja) アルツハイマー氏病を治療するためのＭｎｋインヒビターの使用
US20220313628A1 (en) Methods for selecting phosphatase selective and non-selective phosphatase inhibitors
Chattopadhaya et al. Role of FK506 binding proteins in neurodegenerative disorders
Liu et al. Development of bisindole-substituted aminopyrazoles as novel GSK-3β inhibitors with suppressive effects against microglial inflammation and oxidative neurotoxicity
AU2017200078B2 (en) Treatment of neurodegenerative diseases through inhibition of Hsp90
WO2013149976A1 (en) Indole-pyrimidine derivatives and their therapeutic uses
WO2013167635A1 (en) Therapeutic use of indole-dihydro-imidazole derivatives